Patent · US Active

Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination

US12186275B2 · kind B2 · utility

0Cited by

0References

29Claims

0Family size

Assignee

BioNTach Ceil & Gene Therapies GmbH and TRON—Translationaie Onkologie an der Universitaismedizin der Johannes Gutenberg-univer · DE

Inventors

Ugur Sahin · Mainz, DE
Katharina REINHARD · Mainz, DE
Petra Simon · Mainz, DE
Karolina Anna Mroz · Wiesbaden, DE
Kathleen HOBOHM · Kelkheim, DE

Key dates

Filing date	Aug 7, 2020
Grant date	Jan 7, 2025
Priority date	—
Expiry date	May 28, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.